These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Kim YS; Kim YJ; Lee JM; Han SH; Ko HJ; Park HJ; Pereboev A; Nguyen HH; Kang CY Hum Gene Ther; 2010 Dec; 21(12):1697-706. PubMed ID: 20604681 [TBL] [Abstract][Full Text] [Related]
7. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Korokhov N; Noureddini SC; Curiel DT; Santegoets SJ; Scheper RJ; de Gruijl TD Mol Pharm; 2005; 2(3):218-23. PubMed ID: 15934782 [TBL] [Abstract][Full Text] [Related]
8. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088 [TBL] [Abstract][Full Text] [Related]
9. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245 [TBL] [Abstract][Full Text] [Related]
10. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model. Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203 [TBL] [Abstract][Full Text] [Related]
11. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Korokhov N; de Gruijl TD; Aldrich WA; Triozzi PL; Banerjee PT; Gillies SD; Curiel TJ; Douglas JT; Scheper RJ; Curiel DT Cancer Biol Ther; 2005 Mar; 4(3):289-94. PubMed ID: 15753654 [TBL] [Abstract][Full Text] [Related]
12. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823 [TBL] [Abstract][Full Text] [Related]
13. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Hangalapura BN; Oosterhoff D; de Groot J; Boon L; Tüting T; van den Eertwegh AJ; Gerritsen WR; van Beusechem VW; Pereboev A; Curiel DT; Scheper RJ; de Gruijl TD Cancer Res; 2011 Sep; 71(17):5827-37. PubMed ID: 21747119 [TBL] [Abstract][Full Text] [Related]
14. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356 [TBL] [Abstract][Full Text] [Related]
15. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Pereboev AV; Nagle JM; Shakhmatov MA; Triozzi PL; Matthews QL; Kawakami Y; Curiel DT; Blackwell JL Mol Ther; 2004 May; 9(5):712-20. PubMed ID: 15120332 [TBL] [Abstract][Full Text] [Related]